All In Biotech

Drug Trial Radar · NCT02563327

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,516 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,516

Actual

Start

Jan 25, 2016

Primary completion

Aug 30, 2021

Study completion Aug 30, 2021

Sponsor

Sponsor type
Federal agency
Collaborators
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
First posted
Sep 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Tuberculosis Trials Consortium (TBTC) Study 31 is a phase 3 trial evaluating rifapentine-containing regimens for treatment-shortening of drug-susceptible pulmonary tuberculosis. This pharmacokinetic/pharmacodynamic (PK/PD) substudy evaluates rifapentine and moxifloxacin exposure-response relationships for efficacy and safety outcomes. Intensive and sparse PK sampling are performed among participants receiving rifapentine-containing regimens. PK and clinical outcomes data are used to characterize population pharmacokinetics and assess relationships between drug exposure, culture conversion, treatment failure or relapse, and adverse events.

Conditions

  • Tuberculosis

Interventions

  • RifapentineDrug

    A rifamycin with activity against Mycobacterium tuberculosis

  • MoxifloxacinDrug

    A fluoroquinolone

  • RifampinDrug

    A rifamycin with activity against Mycobacterium tuberculosis

  • IsoniazidDrug

    An anti-tuberculosis agent

  • PyrazinamideDrug

    An anti-tuberculosis agent

  • EthambutolDrug

    An anti-tuberculosis agent

  • PyridoxineDietary supplement

    An essential vitamin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rifapentine Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24)Time frame: Plasma concentrations measured at approximately 0.5, 3, 5, 9, 12, and 24 hours after the pharmacokinetic reference dose during Weeks 2-8 after treatment initiation.
  2. Rifapentine Maximum Plasma Concentration (Cmax)Time frame: Plasma concentrations measured during 0-24 hours following the pharmacokinetic reference dose; PK sampling performed during Weeks 2-8 after treatment initiation.

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Texas Health Science Center at

    San Antonio, Texas

  • Joint Clinical Research Centre/ Makerere Univ Med Sch

    Kampala, Uganda

  • National TB Program

    Hanoi, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.